Clinical profile of drug-sensitive Tuberculosis patients at a Simpang Kawat Public Health Center in Jambi
DOI:
https://doi.org/10.22437/proca.v1i2.50508Keywords:
Clinical profile; drug-sensitive; tuberculosis; public health centerAbstract
Background: Tuberculosis (TB) remains a major public health burden as an infectious and contagious disease. Objective: This study aimed to determine the clinical profile of drug-sensitive TB patients in Jambi City. Methods: An observational cross-sectional study was conducted using medical record data from January 2024 to October 2024 at Simpang Kawat Public Health Center, Jambi City. Data were analyzed with SPSS version 30.0. Results: A total of 35 TB patients with drug-sensitive status were included. Most were male (57.1%), aged <60 years (68.4%) with a mean age of 49.57 ± 15.31 years (mean ± SD), employed (51.4%), married (80%), and without comorbidities (65.7%). The mean body mass index (BMI) was 19.39 ± 3.88 kg/m² (mean ± SD). The majority were new TB cases (88.6%), non-smokers (62.9%), and received standard therapy (2HRZE/4HR), with most patients (60.0%) in the intensive phase taking three tablets once daily. Conclusion: The majority of TB patients in this setting were new cases and drug-sensitive. Strengthening early screening strategies is crucial for optimizing new case detection and ensuring timely management.
Downloads
References
[1] World Health Organization. Global tuberculosis report 2024. Geneva; 2024. 1–69 p.
[2] Burhan E, Karyana M, Karuniawati A, Kusmiati T, Wibisono BH, Handayani D, et al. Characteristics of Drug-sensitive and Drug-resistant Tuberculosis Cases among Adults at Tuberculosis Referral Hospitals in Indonesia. Am J Trop Med Hyg. 2022;107(5):984–91.
[3] Iswari A, Endarti D, Trijayanti C, Haris RNH, Imansari ANR. Analisis Biaya Penyakit Tuberkulosis: Studi Kasus di Salah Satu Puskesmas dan Rumah Sakit di Yogyakarta. Maj Farm. 2020;16(2):211.
[4] Windiyaningsih C, Abidin Z, Murtiani F. Faktor-Faktor yang Berhubungan dengan Kepatuhan Berobat Pada Penderita Tuberkulosis Paru. 2017;4(1).
[5] Izhar MD, Butar MB, Hidayati F, Ruwayda R. Predictors and health-related quality of life with short form-36 for multidrug-resistant tuberculosis patients in Jambi, Indonesia: A case-control study. Clin Epidemiol Glob Heal [Internet]. 2021;12(September):100872. Available from: https://doi.org/10.1016/j.cegh.2021.100872
[6] Kementerian Kesehatan. Buku Panduan Tenaga Medis dan Tenaga Kesehatan Tuberkulosis. 2025;
[7] Sadikin BG, Harbuwono DS. Buku Panduan Kader Tuberkulosis. Kementeri Kesehat RI. 2025;1–56.
[8] Elsayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 6. Glycemic Targets: Standards of Care in Diabetes—2023. Diabetes Care [Internet]. 2023;46(January):S97–110. Available from: http://diabetesjournals.org/care/article-pdf/46/Supplement_1/S97/693609/dc23s006.pdf by guest on 10 October 2023
[9] PERKENI. Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia 2021. Juli 2021. PERKENI, editor. Jakarta: PB. PERKENI; 2021. 1–119 p.
[10] Weimann A, Braga M, Carli F, Higashiguchi T, Hübner M, Klek S, et al. ESPEN practical guideline: Clinical nutrition in surgery. Clin Nutr [Internet]. 2021;40(7):4745–61. Available from: https://doi.org/10.1016/j.clnu.2021.03.031
[11] Yoon JL, Cho JJ, Park KM, Noh HM, Park YS. Diagnostic performance of body mass index using the western pacific regional office of world health organization reference standards for body fat percentage. J Korean Med Sci. 2015;30(2):162–6.
[12] Feng JY, Huang SF, Ting WY, Chen YC, Lin YY, Huang RM, et al. Gender differences in treatment outcomes of tuberculosis patients in Taiwan: A prospective observational study. Clin Microbiol Infect. 2012;18(9).
[13] Murphy ME, Wills GH, Murthy S, Louw C, Bateson ALC, Hunt RD, et al. Gender differences in tuberculosis treatment outcomes: A post hoc analysis of the REMoxTB study. BMC Med. 2018;16(1):1–11.
[14] Bonadonna L V., Saunders MJ, Guio H, Zegarra R, Evans CA. Socioeconomic and behavioral factors associated with tuberculosis diagnostic delay in Lima, Peru. Am J Trop Med Hyg. 2018;98(6):1614–23.
[15] Barter DM, Agboola SO, Murray MB, Bärnighausen T. Tuberculosis and poverty: The contribution of patient costs in sub-Saharan Africa - A systematic review. BMC Public Health. 2012;12(1).
[16] Woldemichael B, Darega J, Dida N, Tesfaye T. Treatment outcomes of tuberculosis patients and associated factors in Bale Zone, Southeast Ethiopia: a retrospective study. J Int Med Res. 2021;49(2).
[17] Kemenkes. Laporan Hasil Studi Inventori Tuberkulosis Indonesia. 2024;10.
[18] Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM, et al. WHO’s new end TB strategy. Lancet. 2015;385(9979):1799–801.
[19] Bhatia V, Srivastava R, Reddy KS, Sharma M, Mandal PP, Chhabra N, et al. Ending TB in Southeast Asia: Current resources are not enough. BMJ Glob Heal. 2020;5(3):1–11.
[20] WHO. WHO consolidated guidelines on tuberculosis. WHO Press. 2022. 98 p.
[21] Chiang CY, Centis R, Migliori GB. Drug-resistant tuberculosis: Past, present, future. Respirology. 2010;15(3):413–32.
[22] Iseman MD. Tuberculosis therapy: Past, present and future. Eur Respir Journal, Suppl. 2002;20(36):87–94.
[23] Bendre AD, Peters PJ, Kumar J. Tuberculosis: Past, present and future of the treatment and drug discovery research. Curr Res Pharmacol Drug Discov [Internet]. 2021;2(May):100037. Available from: https://doi.org/10.1016/j.crphar.2021.100037
[24] Lönnroth K, Williams BG, Cegielski P, Dye C. A consistent log-linear relationship between tuberculosis incidence and body mass index. Int J Epidemiol. 2010;39(1):149–55.
[25] Nasution HS, Halim R. Tuberculosis Case Finding And Diabetes Mellitus Screening In Vulnerable Populations Budi Luhur Nursing Home Jambi. Interes J Ilmu Kesehat. 2021;10(1):55–64.
[26] Moran E, Baharani J, Dedicoat M, Robinson E, Smith G, Bhomra P, et al. Risk factors associated with the development of active tuberculosis among patients with advanced chronic kidney disease. J Infect [Internet]. 2018;77(4):291–5. Available from: https://doi.org/10.1016/j.jinf.2018.06.003
[27] Wang EY, Arrazola RA, Mathema B, Ahluwalia IB, Mase SR. The impact of smoking on tuberculosis treatment outcomes: A meta-analysis. Int J Tuberc Lung Dis. 2020;24(2):170–5.
[28] Nisa T, Sari V. Effect of Smoking on Tuberculosis Treatment Failure: Meta-Analysis. J Epidemiol Public Heal. 2022;7(2):251–62.
[29] Kumar Nathella P, Babu S. Influence of diabetes mellitus on immunity to human tuberculosis. Immunology. 2017;152(1):13–24.
[30] Siddiqui AN, Hussain S, Siddiqui N, Khayyam KU, Tabrez S, Sharma M. Detrimental association between diabetes and tuberculosis: An unresolved double trouble. Diabetes Metab Syndr Clin Res Rev [Internet]. 2018;12(6):1101–7. Available from: https://doi.org/10.1016/j.dsx.2018.05.009
[31] Naghavi M, Ong KL, Aali A, Ababneh HS, Abate YH, Abbafati C, et al. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403:1990–2021.
[32] WHO. Operational Handbook on Tuberculosis [Internet]. Module 5: management of tuberculosis in children and adolescents. 2022. 56 p. Available from: https://apps.who.int/iris/bitstream/handle/10665/340256/9789240022614-eng.pdf
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Fitrianingsih, Elisma, Muhammad Syukri, Yuliawati, Uce Lestari, Afifah Azzahra, Dinda Arum Carolina Dewi
This work is licensed under a Creative Commons Attribution 4.0 International License.
Published with license by LPPM Universitas Jambi. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International (CC BY 4.0 International). This license enables reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator.
